Use of zoledronic acid in the treatment of Múltiple Myeloma
Abstract
The main objective of the case was whether the use of bisphosphonates in the treatment of multiple myeloma is effective for decreasing pain in patient and to evaluate the reduction of hypercalcemia or not. We have studied a case of a patient undergoing chemotherapy and contributed to â Zometaâ in the Regional Hospital of Baza (Granada-Spain), during the first session of treatment the patient revealed favourable results as evidenced decreased incidence of hypercalcemia and pain reduction. After an exhaustive assessment of the patient, three nursing diagnoses were selected; the most appropriate interventions for each of these diagnoses were planned, using NANDA taxonomy, NIC and NOC taxonomy.
During treatment the patient had some variation in body temperature and insignificant nausea in the first sessions, as well as decreased pain which led to use less analgesics, normalization of serum calcium levels and an increase in her quality of life. The findings of the study identified a positive effect on the administration of Zoledronic Acid as the expected results were obtained and the side effects were minimal, without interrupting the treatment.
Downloads
The works published in this magazine are subject to the following terms:
1. The Publications Service of the University of Murcia (the publisher) preserves the copyright of the published works, and encourages and allows the reuse of the works under the license for use stated in point 2.
© Servicio de Publicaciones, Universidad de Murcia, 2011 (© Publications Service, University of Murcia, 2011)
2. The works are published in the electronic edition of the journal under Creative Commons Reconocimiento-NoComercial-SinObraDerivada 3.0 España(texto legal) “ a Attribution-NonCommercial-NoDerivatives 3.0 Spain license (legal text)”. They can be copied, used, broadcasted, transmitted and publicly displayed, provided that: i) the authorship and original source of their publication (journal, publisher and URL) are cited; (ii) are not used for commercial purposes; iii) the existence and specifications of this license is mentioned.
3. Conditions of self-archiving. Authors are allowed and encouraged to electronically disseminate the pre-print (pre-reviewed ) and / or post-print (reviewed and accepted for publication) versions of their works prior to publication, as it ensures a wider circulation and dissemination which may lead to a possible increase in its mention and a higher scope among the academic community. RoMEO color: green.